Independent Accountability Tracker
Curated news, regulatory actions, and research impacting the U.S. organ procurement system. Updated weekly from federal, academic, and industry sources.
Nasdaq / Google News · Feb 28, 2026
TransMedics, the maker of the Organ Care System (OCS) for ex-vivo organ perfusion, is attracting investor attention as a high-growth play in transplant technology. The company's portable perfusion devices are expanding the geographic reach of organ procurement by keeping organs viable during longer transport times — a direct impact on OPO logistics and donor utilization rates.
BIOENGINEER.ORG / Google News · Feb 27, 2026
New analysis documents the rapid growth of donation after circulatory death (DCD) in the United States. DCD now accounts for a growing share of all organ donors, driven by expanded protocols for DCD heart and lung recovery. For OPOs, the DCD trend means evolving surgical coordination requirements and the need for updated training on withdrawal-to-procurement timelines.
ABC27 / Google News · Feb 26, 2026
Policy changes are accelerating the shift toward donation after circulatory death (DCD) as a growing source of transplantable organs. As DCD protocols expand beyond kidneys and livers to include hearts and lungs, OPOs face new operational requirements around rapid recovery logistics and hospital partnerships for controlled withdrawal scenarios.
News-Medical / Google News · Feb 26, 2026
Research identifies disrupted lymphatic vessels as a potential driver of chronic transplant rejection, one of the leading causes of graft loss. Understanding this mechanism could lead to new preservation techniques that protect lymphatic integrity during organ recovery — directly relevant to OPO procurement protocols and organ viability assessment.
The Business Journals / Google News · Feb 26, 2026
An organ procurement organization is investing $2.3 million to relocate its headquarters from West Sacramento to North Natomas. The move signals continued investment in OPO infrastructure and operational capacity, reflecting the industry's growth trajectory as donation volumes reach record levels.
AJMC / Google News · Feb 26, 2026
A study finds that azathioprine, a common immunosuppressive drug used post-transplant, is linked to increased squamous cell carcinoma risk in organ transplant recipients. While this primarily affects transplant centers and recipient care, it underscores the downstream consequences of organ procurement decisions and the importance of optimizing donor-recipient matching.
The Heartland Institute / Google News · Feb 24, 2026
New policy changes are giving organ procurement organizations faster access to potential donors' medical records, removing a critical bottleneck in the referral-to-recovery timeline. Faster record access enables OPOs to evaluate donor suitability more quickly, potentially increasing organ utilization rates and reducing cold ischemia time.
ABC4 Utah / Google News · Feb 23, 2026
Intermountain Health's transplant program in Utah surpassed 500 organ transplants in 2025, marking a significant milestone for the Mountain West region. The achievement reflects growing transplant volumes nationally and the expanding capacity of regional programs that rely on OPO partnerships for organ procurement.
Federal Register · Feb 19, 2026
CMS published notices for five hospitals seeking waivers to work with an OPO other than their federally designated one — including Hugh Chatham Memorial, Lexington Medical Center, Alleghany County Memorial, WRMC, and High Point Regional. A cluster of waiver requests like this can signal hospital dissatisfaction with their designated OPO's performance or responsiveness.
Federal Register · Jan 30, 2026
CMS has published a proposed rule to revise the Conditions for Coverage (CfC) for OPOs, aimed at clarifying procedural questions and enabling OPOs to make better-informed decisions for higher performance. This is the most significant regulatory update since the 2020 Final Rule that introduced outcome-based metrics. OPOs should review and submit comments — the revisions will directly impact recertification criteria and performance measurement.
Federal Register · Dec 11, 2025
CMS proposes revisions to the IOTA Model for Performance Year 2, which tests whether performance-based payments to kidney transplant hospitals can increase transplant access. The IOTA Model directly affects OPO-hospital relationships by creating financial incentives for hospitals to accept more kidneys, potentially shifting referral patterns and organ offer acceptance rates.
Federal Register · Dec 4, 2024
CMS finalized the IOTA Model, a mandatory alternative payment model that tests whether performance-based financial risk for kidney transplant hospitals increases transplant access. Participating hospitals face upside or downside payments based on transplant volume metrics. This creates new dynamics for OPO-hospital coordination — hospitals under IOTA pressure will likely become more aggressive in accepting organ offers.
Weekly intelligence for OPO professionals. Regulatory updates, research breakthroughs, and industry accountability — in your inbox every Tuesday.